Bayer Group
News Overview
November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
Bayer CropScience completes acquisition of biotech company Athenix Corp.
» more
October 27, 2009
News Conference Call for the Third Quarter of 2009
Address by Werner Wenning
» more
Address by Werner Wenning
» more
October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
» more
1:15 min.
Bayer back on the uptrend
» more
1:15 min.
October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
» more
October 9, 2009
Improvement in orders
Bayer MaterialScience AG ends reduced working hours at German sites
» more
Bayer MaterialScience AG ends reduced working hours at German sites
» more
September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
1:13 min.
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
» more
1:13 min.
September 22, 2009
Once again included in the Carbon Disclosure Leadership Index
Bayer honored as world’s best company in climate protection
» more
1:19 min.
Bayer honored as world’s best company in climate protection
» more
1:19 min.
September 17, 2009
Greater focus on future technologies:
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
» more
1:49 min.
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
» more
1:49 min.
September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
» more
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
» more
September 15, 2009
Bayer Supervisory Board decides company’s future management line-up:
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
» more
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
» more
September 4, 2009
Bayer again included in the Dow Jones Sustainability World Index:
Bayer remains “best in class” in sustainability
» more
Bayer remains “best in class” in sustainability
» more
September 3, 2009
August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
» more
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
» more
August 19, 2009
Trait platform with extensive product pipeline to deliver innovative solutions for farmers:
Bayer CropScience acquires US biotech company Athenix Corp.
» more
1:17 min.
Bayer CropScience acquires US biotech company Athenix Corp.
» more
1:17 min.
July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
» more
Bayer robust in a difficult environment
» more
July 22, 2009
July 21, 2009
Long-term cooperation with leading Australian research institute CSIRO:
Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals
» more
1:04 min.
Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals
» more
1:04 min.
July 14, 2009
New Drug Application for Rivaroxaban in the U.S.:
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA
» more
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA
» more
July 9, 2009
Expansion of diabetes portfolio in growth market China:
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
» more
1:14 min.
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
» more
1:14 min.